These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 13571110)

  • 21. Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis.
    Ozcan D; Seçkin D; Allahverdiyev AM; Weina PJ; Aydin H; Ozçay F; Haberal M
    Pediatr Transplant; 2007 Mar; 11(2):228-32. PubMed ID: 17300508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Visceral leishmaniasis: time to better use existing resources.
    Reithinger R; Brooker S; Kolaczinski JH
    Lancet; 2009 Oct; 374(9698):1330. PubMed ID: 19837253
    [No Abstract]   [Full Text] [Related]  

  • 23. Renal function improvement with pentavalent antimonial agents in patients with visceral leishmaniasis.
    Daher EF; Rocha NA; Oliveira MJ; Franco LF; Oliveira JL; Silva Junior GB; Abreu KL; Henn GA; Martins AM; Libório AB
    Am J Nephrol; 2011; 33(4):332-6. PubMed ID: 21411988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Leishmaniasis. German Society for Pediatric Infectious Diseases (DGPI), Parasitology Working Group].
    Klin Padiatr; 1998; 210(6):428-9. PubMed ID: 9871902
    [No Abstract]   [Full Text] [Related]  

  • 25. The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis.
    Wasunna M; Musa A; Hailu A; Khalil EA; Olobo J; Juma R; Wells S; Alvar J; Balasegaram M
    Trans R Soc Trop Med Hyg; 2016 Jun; 110(6):321-3. PubMed ID: 27268714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Return of kalaazar.
    Seal SC
    Indian J Public Health; 1977; 21(3):109-10. PubMed ID: 615152
    [No Abstract]   [Full Text] [Related]  

  • 27. [Development of antibodies in children treated for visceral leishmaniasis].
    Mokrani T; Belazzoug S; Bouzid Z; Keddari M
    Arch Inst Pasteur Alger; 1988; 56():101-7. PubMed ID: 3077240
    [No Abstract]   [Full Text] [Related]  

  • 28. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony.
    Harms G; Zwingenberger K; Sandkamp B; Omena S; Pedrosa C; Richter J; Rosenkaimer F; Feldmeier H; Bienzle U
    J Interferon Res; 1993 Feb; 13(1):39-41. PubMed ID: 8454909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Visceral leishmaniasis in 2 Swedish tourists after travel to Greece].
    Hellgren U; Lundbergh P
    Lakartidningen; 1986 Jun; 83(26-27):2395-6. PubMed ID: 3736285
    [No Abstract]   [Full Text] [Related]  

  • 31. Translating immune cell cross-talk into a treatment opportunity for visceral leishmaniasis.
    Ali N; Bhattacharya P
    Immunotherapy; 2013 Oct; 5(10):1025-7. PubMed ID: 24088071
    [No Abstract]   [Full Text] [Related]  

  • 32. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable.
    Bhattacharya SK; Sur D; Sinha PK; Karbwang J
    Indian J Med Res; 2006 Mar; 123(3):195-6. PubMed ID: 16778303
    [No Abstract]   [Full Text] [Related]  

  • 34. Visceral leishmaniasis: an opportunistic infection in haematological malignancy.
    Pati HP; Kashyap R; Choudhry VP; Mohapatra M
    Haematologia (Budap); 1999; 29(4):295-300. PubMed ID: 10438069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in visceral leishmaniasis in China.
    Guan LR; Shen WX
    Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):291-8. PubMed ID: 1818378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of visceral leishmaniasis in Oltenia region (Romania).
    Găman A; Dobrea C; Găman G
    Rom J Morphol Embryol; 2010; 51(2):391-4. PubMed ID: 20495762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of three culture media for isolating Leishmania donovani from splenic aspirates in Kenyan visceral leishmaniasis.
    Githure JI; Oster CN; Chulay JD
    East Afr Med J; 1984 Jul; 61(7):539-43. PubMed ID: 6545198
    [No Abstract]   [Full Text] [Related]  

  • 38. [Anthropologic research and understanding pediatric visceral leishmaniasis in Tunisia].
    Bouratbine A; Moussa H; Aoun K; Ben Ismaïl R
    Bull Soc Pathol Exot; 1998; 91(2):183-7. PubMed ID: 9642482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis.
    Boelaert M; Lynen L; Desjeux P; Van der Stuyft P
    Bull World Health Organ; 1999; 77(8):667-74. PubMed ID: 10516788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visceral leishmaniasis.
    van Griensven J; Diro E
    Infect Dis Clin North Am; 2012 Jun; 26(2):309-22. PubMed ID: 22632641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.